(Q39327784)

11 September 2017

title

C-Met in invasive breast cancer: is there a relationship with the basal-like subtype? (English)

1 reference

11 September 2017

Adam R Brentnall

4

0 references

Emad A. Rakha

object named as

Emad A Rakha

3

0 references

Andrew Green

object named as

Andrew R Green

2

0 references

Ian Ellis

object named as

Ian O Ellis

5

0 references

author name string

Colan M Ho-Yen

1

1 reference

11 September 2017

Stephanie Kermorgant

6

1 reference

11 September 2017

J L Jones

7

1 reference

11 September 2017

language of work or name

English

0 references

publication date

21 October 2013

1 reference

11 September 2017

1 reference

11 September 2017

volume

120

1 reference

11 September 2017

issue

2

1 reference

11 September 2017

page(s)

163-171

1 reference

Molecular portraits of human breast tumours

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Molecular stratification of triple-negative breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Epidemiology of basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

The function, proteolytic processing, and histopathology of Met in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

The Met oncogene and basal-like breast cancer: another culprit to watch out for?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

From Tpr-Met to Met, tumorigenesis and tubes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Hepatocyte growth factor twenty years on: Much more than a growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Crosstalk in Met receptor oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

MET mutations in cancers of unknown primary origin (CUPs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Expression of c-met is a strong independent prognostic factor in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Targeting MET in cancer: rationale and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Tissue microarrays for high-throughput molecular profiling of tumor specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Gene expression profiling of breast cell lines identifies potential new basal markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Basal cytokeratin expression in relation to biological factors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

Expression of scatter factor and c-met receptor in benign and malignant breast tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

7 January 2021

X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

7 January 2021

Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

7 January 2021

c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

7 January 2021

Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

7 January 2021

Definition of a direct extracellular interaction between Met and E-cadherin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28386

7 January 2021

Identifiers

DOI

10.1002/CNCR.28386

1 reference

11 September 2017

1 reference